It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their U.S.

Merck MRK along with partner Eisai announced data from the phase III LEAP-015 study, which evaluated blockbuster PD-1 ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

The healthcare giant is dealing with the fast-approaching patent cliff for its most important product, cancer medicine ...

The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begins in 2028.

Summit Therapeutics has soared due to hopes around its cancer drug candidate, ivonescimab. It outperformed Keytruda in a phase 3 trial for treating advanced non-small cell lung cancer. Investors ...

MRK posts encouraging Q4 results. However, the decision to temporarily halt shipments of Gardasil vaccines to China has ...

4Q Earnings: $3.7 billion (loss of $1.2 billion 4Q23) FY Earnings: $17.1 billion (earnings were $365 million FY23) ...

Keytruda’s sales are gaining from rapid uptake across earlier-stage indications, mainly early-stage non-small cell lung cancer (“NSCLC”). Continued strong momentum in metastatic indications ...